Show simple item record

FieldValueLanguage
dc.contributor.authorRoche, Michael
dc.contributor.authorSalimi, Hamid
dc.contributor.authorDuncan, Renee
dc.contributor.authorWilkinson, Brendan L.
dc.contributor.authorChikere, Kelechi
dc.contributor.authorMoore, Miranda S.
dc.contributor.authorWebb, Nicholas E.
dc.contributor.authorZappi, Helena
dc.contributor.authorSterjovski, Jasminka
dc.contributor.authorFlynn, Jacqueline K.
dc.contributor.authorEllett, Anne
dc.contributor.authorGray, Lachlan R.
dc.contributor.authorLee, Benhur
dc.contributor.authorJubb, Becky
dc.contributor.authorWestby, Mike
dc.contributor.authorRamsland, Paul A.
dc.contributor.authorLewin, Sharon R.
dc.contributor.authorPayne, Richard J.
dc.contributor.authorChurchull, Melissa J.
dc.contributor.authorGorry, Paul R.
dc.date.accessioned2020-06-19
dc.date.available2020-06-19
dc.date.issued2013-04-20
dc.identifier.urihttps://retrovirology.biomedcentral.com/articles/10.1186/1742-4690-10-43
dc.identifier.urihttps://hdl.handle.net/2123/22626
dc.description.abstractThe CCR5 antagonist maraviroc (MVC) inhibits human immunodeficiency virus type 1 (HIV-1) entry by altering the CCR5 extracellular loops (ECL), such that the gp120 envelope glycoproteins (Env) no longer recognize CCR5. The mechanisms of HIV-1 resistance to MVC, the only CCR5 antagonist licensed for clinical use are poorly understood, with insights into MVC resistance almost exclusively limited to knowledge obtained from in vitro studies or from studies of resistance to other CCR5 antagonists. To more precisely understand mechanisms of resistance to MVC in vivo, we characterized Envs isolated from 2 subjects who experienced virologic failure on MVC.en_AU
dc.language.isoen_USen_AU
dc.publisherBioMed Centralen_AU
dc.subjectHIV-1en_AU
dc.subjectMaravirocen_AU
dc.subjectResistanceen_AU
dc.subjectEnven_AU
dc.subjectgp120en_AU
dc.subjectV3loopen_AU
dc.subjectCCR5 N-terminusen_AU
dc.subjectCCR5 ECLsen_AU
dc.titleA common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutationsen_AU
dc.typeArticleen_AU
dc.subject.asrcFoR::030599 - Organic Chemistry not elsewhere classifieden_AU
dc.subject.asrcFoR::030499 - Medicinal and Biomolecular Chemistry not elsewhere classifieden_AU
dc.subject.asrcFoR::060199 - Biochemistry and Cell Biology not elsewhere classifieden_AU
dc.identifier.doi10.1186/1742-4690-10-43
dc.type.pubtypePublisher's versionen_AU


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.